ClinicalTrials.gg

Program

sevasemten

Also written as “Sevasemten”, “Sevasemten Dose 1” and “Sevasemten Dose 2”.

Its studies are mostly in Muscular Dystrophy, Duchenne · Muscular Dystrophies, led by Edgewise Therapeutics.

Furthest: phase 2, since Mar 14, 20229 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Edgewise Therapeutics93 open or runningphase 2since Mar 14, 2022Oct 2, 2020Jan 2027phase 2 · NCT05540860

Also a collaborator on its studies: medpace-inc and sysnav.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 2, 2020First study: phase 1 study in Muscular Dystrophy, DuchenneFirst studyNCT04585464 · 127 enrolled · United States
  2. Dec 2, 2021Phase 1 study in Muscular Dystrophy, DuchenneNCT05160415 · 12 enrolled · United States
  3. Mar 14, 2022Phase 2 study in Muscular Dystrophy, DuchenneNCT05291091 · 244 enrolled · United States, Australia, Belgium and more
  4. Aug 5, 2022Phase 1 study in Muscular DystrophiesNCT05492734 · 10 enrolled · United States
  5. Sep 6, 2022Phase 2 study in Muscular Dystrophy, DuchenneNCT05540860 · 76 enrolled · United States
  6. Feb 7, 2023Phase 1 study in Muscular DystrophiesNCT05730842 · 15 enrolled · United States
  7. Sep 27, 2023Phase 2 study in Muscular Dystrophy, DuchenneNCT06066580 · 260 planned · United States, Australia, Belgium and more
  8. Oct 20, 2023Phase 2 study in Muscular Dystrophy, DuchenneNCT06100887 · 43 enrolled · United States
  9. Feb 13, 2025Phase 1 study in Healthy SubjectsNCT06916897 · 42 enrolled · United States

Ahead

  1. Jan 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT05540860
  2. Mar 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06100887
  3. Feb 2031Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06066580

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06916897Healthy Subjects · United States1CompletedFeb 22, 202542
NCT06100887Muscular Dystrophy, Duchenne · United States2Active, not recruitingMar 202743
NCT06066580Muscular Dystrophy, Duchenne · United States, Australia, Belgium and more2By invitationFeb 2031260
NCT05730842Muscular Dystrophies · United States1CompletedApr 6, 202315
NCT05540860Muscular Dystrophy, Duchenne · United States2Active, not recruitingJan 202776
NCT05492734Muscular Dystrophies · United States1CompletedAug 19, 202210
NCT05291091Muscular Dystrophy, Duchenne · United States, Australia, Belgium and more2CompletedSep 7, 2026244
NCT05160415Muscular Dystrophy, Duchenne · United States1CompletedMar 1, 202412
NCT04585464Muscular Dystrophy, Duchenne · United States1CompletedNov 15, 2021127

How it is read

Names in the registry

  • “Sevasemten”, 2 entries
  • “Sevasemten Dose 1”, 2 entries
  • “Sevasemten Dose 2”, 2 entries
  • “Sevasemten Dose 3”, 2 entries
  • “EDG-5506”, 2 entries

Codes read as this program: EDG5506.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.